Skip to content
BioCentury This Week cover art

All episodes

BioCentury This Week, 407 episodes. Page 2 of 5.

#
Title
101

Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO

102

Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights

103

Ep. 295 - Bio€quity Europe 2025 Preview

104

Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing

105

Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

106

Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview

107

Ep. 291 - Grand Rounds - U.S. Preview

108

Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed

109

Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA

110

Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview

111

Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI

112

Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs

113

Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play

114

Ep. 284 - Takeaways from the East-West Summit

115

Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI

116

Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity

117

Ep. 281 - Roche Reboot and 5 Things on Trump 2.0

118

Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs

119

Ep. 279 - East-West Summit Preview

120

Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine

121

Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug

122

Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

123

Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

124

Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI

125

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

126

Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

127

Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure

128

Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

129

Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

130

Ep. 269 - Trends in VC Funds, Obesity Start-ups and More

131

Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal

132

Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts

133

Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update

134

Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

135

Ep. 264 - Prepping for Trump & Alzheimer's Ethics

136

Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

137

Ep. 262 - EGFR Case Study, FDA & Politics

138

Ep. 261 - China Summit: Reinventing Your China Strategy

139

Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

140

Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

141

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

142

Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

143

Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary

144

Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss

145

Ep. 254 - Takeaways from Grand Rounds 2024

146

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

147

Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

148

Ep. 251 - Eyes on the target: a Back to School Overview

149

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

150

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

151

Ep. 248 - Grand Rounds Preview: Eyes on the Target

152

Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School

153

Ep. 246 - Wilson’s Vision for Gene Therapy. Plus: Korea Biotech & Grand Rounds

154

Ep. 245 - Biotech-Academia Deals, Leqembi's Latest, Wilson Moves On

155

Ep. 244 - Leqembi's Thumbs-Down in Europe. Plus: Perioperative Cancer, Pediatric Review Vouchers

156

Ep. 243 - Radiopharma Alpha Emitters, AZ’s Galbraith and LNPs

157

Ep. 242 - 3Q Markets Preview, Washington Update, Lisa Burns

158

Ep. 241 - U.K. Biopharma on the Move. Plus: IRA, Biosecure

159

Ep. 240 - Chevron Ruling's Impact. Plus: Tumor Targets, Lurie Winner

160

Ep. 239 - Rare Disease Spotlight: MPS & DMD

161

Ep. 238 - Biosecure Act: The Impact & What's Ahead

162

Ep. 237- Pandemic Prep Problems, Reverse Mergers, Alzheimer’s & SCOTUS

163

Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera, Radiopharma

164

Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations

165

Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update

166

Ep. 233 - ASCO Preview, Rare Diseases & Biogen M&A

167

Ep. 232 - Shake up at BIO. Plus: ASGCT highlights, new IPF & obesity data

168

Bonus Content - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more

169

Ep. 231 - Biosecure Revised. Plus: Venture Rounds, Deals of Note

170

Bonus Content - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise

171

Ep. 230 - Bio€quity Europe 2024 Preview

172

Ep. 229 - ASGCT Preview, Accelerated Approval Plus: The Latest in Biosecure

173

Ep. 228 - Energizing Gene Therapy. Plus: AI Newco, Ono-Deciphera

174

Ep. 227 - Defending Accelerated Approval. Plus: Endpoint Innovation & AIM Amiss

175

Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture & IRA Tea Leaves

176

Ep. 225 - 2Q Markets Preview & AACR Takeaways

177

Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

178

Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

179

Ep. 222 - Crowley’s Vision for BIO, Plus: MASH & CAR Ts

180

Ep. 221 - China Biocontroversy, Plus: Diversity Matters

181

Ep. 220 - Biotech’s Financing Flurry & Distillery Spotlight

182

Ep. 219 - East-West Summit Preview

183

Ep. 218 - Bob Nelsen Insights, TL1A, Rare Diseases

184

Ep. 217 - Safer CAR Ts & World’s First TIL Therapy

185

Ep. 216 - Anti-China Biotech Policy: Biosecure & Beyond

186

Ep. 215 - ADCs, Psychedelics & IPOs

187

Ep. 214 - BMS’s Patent Cliff, Congress Targets China Biotech

188

Ep. 213 - Biotech IPOs & IL-18 Momentum

189

Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact

190

Ep. 211 - 2024 Markets Preview, Woodcock's Legacy

191

Ep. 210 - J.P. Morgan Healthcare Conference Wrap

192

Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024

193

Ep. 208 - XBI Rally, ASH Highlights & '24 Picks

194

Ep. 207 - Sickle Cell, AbbVie Deals, BIO CEO, March-in

195

Ep. 206 - Roche, AbbVie Deals; Plus: FDA & CAR T

196

Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech

197

Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans

198

Ep. 203 - POC for Verve? Plus: IRA & East-West Deals

199

Ep. 202 - A DMD Decision & Endpoint Innovation

200

Ep. 201 - ESMO, NIH & IRA